INTRODUCTION
Mandibulofacial dysostosis (MFD) is defined by abnormal craniofacial development, particularly of the first and second branchial arches. MFD is characterized by malar and mandibular hypoplasia, often associated with cleft palate, conductive hearing loss, and, less frequently, choanal atresia, visceral or skeletal malformations as well as intellectual disability (ID). MFD is not a distinct and specific genetic disease, but is in fact composed of a group of clinically and genetically heterogeneous disorders. Among the several types of MFD, Treacher Collins syndrome (TCS, OMIM 154500) is the most frequent. TCS is also genetically heterogeneous and to date three genes have been implicated in explaining B80% of the genetic anomalies in TCS patients (namely TCOF1, 1 POLR1D 2 and POLR1C 2 ). The remaining genes are still unknown. Heterozygous intragenic deletions/duplications of TCOF1 have been recently described and are a rare cause of TCS. [3] [4] Mutations in EFTUD2 have been identified in patients with MFD and microcephaly 5 (MFDM, OMIM 610536), characterized by progressive and severe microcephaly, ID and additional malformations, such as choanal and aural atresia, cleft palate, congenital heart defect and esophageal atresia. 6 However, Gordon et al 6 and Luquetti et al 7 reported EFTUD2 mutations in patients without microcephaly, suggesting that EFTUD2 could be responsible for MFDM as well as other forms of MFD. 6 We report for the first time two patients with MFD and ID due to the deletion of several genes including TCOF1 and CAMK2A, and discuss the involvement of these genes in the phenotype of the patients.
MATERIALS AND METHODS
Informed consent was obtained from the parents of the patients for molecular genetic analysis, and publication of the clinical data and pictures.
DNA was extracted from the patient's whole blood sample using the QIAamp DNA Blood Midi Kit (Qiagen, Courtaboeuf, France) according to the supplier's protocol.
The 27 coding exons of TCOF1 and at least 60 bp of intronic sequence flanking the exons were amplified and sequenced with Life Technologies reagents and equipment, see Supplementary data for details.
MLPA analysis was performed using the Salsa MLPA Kit P310 TCOF1 (MRC-Holland, Amsterdam, the Netherlands) and carried out as described by the manufacturer with capillary electrophoresis on an ABI 3130 DNA Analyzer (Life Technologies, Courtaboeuf, France), GeneMapper software version 4.0 (Life Technologies) and MRC Coffalyzer MLPA-Dat Software (MRC-Holland). Additional information about commercially available probe sets is available at http://www.mrc-holland.com.
CNV detection was performed using array-CGH Agilent (Agilent Technologies, Les Ulis, France) 180k for patient 1 and array-CGH Agilent 244k for patient 2. Experiments followed standard and manufacturer's recommendations. DNA sequence information refers to the public UCSC database NCBI37 (Hg19). Genome assemblies were NCBI136/hg18 UCSC for patient 1 and GRCh37/hg19 for patient 2.
RESULTS

Clinical reports
Patient 1. She was born at term after a normal pregnancy, to unrelated and unaffected Belgian parents. Birth weight was normal (3100 g, À0.5 SD). Other parameters were unknown. Family history was uneventful. Diagnosis of MFD was made at birth based on malar hypoplasia, down-slanted palpebral fissures, microtia and microretrognathia. The baby had bilateral conductive hearing loss ( À60 dB on the right side and À70 dB on the left side), which was treated with bone-anchored hearing aid implants. She walked at 18 months and spoke with a delay initially attributed to hearing loss. However, she had persistent learning difficulties despite the hearing aid. She was given special schooling and acquired the basics of reading and writing, but had attention deficit, major difficulties in logicalmathematical skills and persistent clumsiness. She also had difficulties in social interaction, but did not present objective autistic features. At the last evaluation at the age of 14 years, growth parameters and head circumference were normal (weight: 55.5 kg, mean (M); height: 160 cm, M; and OFC: 55.5 cm, M). Her facial features fit the diagnosis of MFD, namely down-slanted palpebral fissures with mild colobomatous cleft of the lower lid, small mandible with class III malocclusion and low-set and dysplastic ears ( Figure 1a ). The voice was high pitched and hypernasal.
Patient 2.
He was born at term after a pregnancy marked by maternal smoking (10 cigarettes per day). BW was 2800 g ( À2 SD), BL was 50 cm (M) and BOFC was 35 cm (M). The low weight was attributed to smoking during pregnancy and normalized quickly. Parents were unrelated and unaffected, of French origin with an uneventful family history. TCS was diagnosed at 6 days of life based on facial features. The neonatal period was marked by feeding difficulties due to craniofacial malformation and required nasogastric tube. Newborn neurological examination was normal. The baby had bilateral moderate conductive hearing loss, which was treated with auditory prostheses. He spoke no words at the age of 26 months, and only 3 words at 3 years. The speech delay was initially thought to be due to neglect to wear the hearing aids, but he thereafter developed additional learning difficulties. The patient had a neuro-psychological evaluation at 8.5 years. Performance IQ was at 71, working memory was at 58. He could neither read nor write. He presented behavioral disorders, violence and aggressiveness, and required treatment with risperidone. He attended special classes in an institute for patients with hearing impairment. At the last evaluation ( Figure 1b ) at age 9 years and 11 months, growth, weight and head circumference were in the normal range (135 cm, 30 kg and 54.5 cm). He presented with facial features of MFD, namely down-slanted palpebral fissures, malar hypoplasia, micrognathia and microtia, and mild ID.
Molecular study. Direct sequencing of TCOF1 was negative in both patients. MLPA of TCOF1 showed a complete deletion of the gene in the two patients (Figures 2a and 2b) . For patient 1, MLPA of both parents showed no deletion of TCOF1. For patient 2, only the DNA of the mother was available and MLPA of TCOF1 was normal. CGH array in patient 1 showed a deletion of 1 Mb, encompassing TCOF1, TCOF1 deletion and intellectual disability M Vincent et al GRPEL2, PCYOX1L, IL17B, CSNK1A1, FLJ41603, PPARGC1B, PDE6A, SLC26A2, TIGD6, CSF1R, PDGFRB, CDX1, SLC6A7, CAMK2A, and ARSI (Figure 2c ). CGH array in patient 2 showed a deletion of 262 kb, encompassing TCOF1, CDX1, SLC6A7, CAMK2A, ARSI and CD74 (Figure 2d) . The common deleted genes in the two patients are TCOF1, CAMK2A, CDX1, ARSI and SLC6A7 (Figure 3) . 
DISCUSSION
MFD is a clinically and genetically heterogeneous group of disorders associated with craniofacial features, visceral and/or skeletal malformations and sometimes ID. The clinician's orientation towards the diagnosis of a specific kind of MFD is based on different combinations of these clinical features. Usually the observation of ID in a patient with MFD encourages the clinician to consider a diagnosis other than TCS. Among the etiologies of MFD with ID, the MFDM or MFD Guion-Almeida type was recently linked to mutations in EFTUD2. [5] [6] [7] Here, we report on two patients with MFD, mild ID and normal OFC, sharing a deletion of TCOF1, CAMK2A, CDX1, ARSI and SLC6A7. In an attempt to determine which genes (or combination of genes) are responsible for the phenotype observed in the two patients, we considered the known functions of the genes located in the minimal critical region. TCOF1 encodes for a protein called treacle, which is part of a complex implicated in ribosomal RNA biogenesis and is involved in the proliferation and differentiation of neural crest cells in the first and second branchial arches during early embryogenesis. 8 To our knowledge, mutations in TCOF1 are responsible for the facial features observed in TCS, but have never been reported to cause ID. However, it has been shown recently that Tcof1± mice exhibit reduced brain size as a consequence of defects in neural progenitor maintenance. 9 We believe that deletion of TCOF1 is responsible for the facial features observed in the two patients we reported on. We also believe that the role of TCOF1 in ID observed in the two reported patients is unlikely. Indeed, even if Tcof1 is involved in the control of brain size in mice, patients with haploinsufficiency of TCOF1 by point mutation or intragenic deletion/duplication usually do not present with ID or microcephaly. However, we cannot rule out a combinatorial effect of the deletion of TCOF1 with the other deleted genes.
The CAMK2A gene (OMIM 114078) encodes the alpha subunit of calcium/calmodulin-dependent protein kinase II (CaM kinase II), which is present in abundance in the brain where it constitutes a major constituent of the postsynaptic density. 10 Autophosphorylation of CAMK2A after NMDA receptor activation seems to be essential for contextual long-term memory formation. 11 Different models have shown that CAMK2A is necessary for hippocampal place cell stability ex vivo and for spatial learning, long-term memory, decreased fear response and increase in defensive aggression in vivo. 12 CAMK2A may modulate the synaptic events required for the consolidation of memory traces in cortical networks and may have a critical role in plasticity and learning. 10 Mice heterozygous for a null mutation of Camk2a have profoundly dysregulated behaviors and impaired neuronal development in the dentate gyrus. 13 No heterozygous variant predicting to lead to haploinsufficiency in CAMK2A has been identified in Exome Variant Server (EVS; http://evs.gs. washington.edu). Integrating all these data, we suggest that CAMK2A could be responsible for the ID observed in the two reported patients.
The SLC6A7 gene (OMIM 606205) encodes a neurotransmitter L-Proline transporter and is a member of the g-aminobutyric acid (GABA) neurotransmitter gene family. 14 It is expressed mostly in the hypothalamus and the hippocampus. 15 To date, this gene has been only described as a susceptibility gene for asthma. 14 Based on the known function of this gene (gene belonging to the GABA neurotransmitter family and expressed in the brain), we can only speculate that this gene could participate to the ID observed in the two reported patients. However, two frameshift variants (with unknown modification of function using polyphen web resource) have been observed in EVS.
The caudal-type homeobox transcription factor 1 gene (CDX1, OMIM 600746) is known to be required for anterior-posterior regional identity in Drosophila. In humans, it is an essential transcription factor for intestinal differentiation, and may contribute to intestinal metaplasia in the stomach. 16 No digestive problems were observed in the patients and only one nonsense variant with unknown modification of function using polyphen web resource was observed in EVS. We suggest that this gene is not involved in the phenotype of the two reported patients.
The ARSI gene (OMIM 610009) encodes for arylsulfatase I, which catalyzes the hydrolysis of sulfate esters and is involved in hormone biosynthesis, modulation of cell signaling, and degrading of macromolecules. 17 The pattern of expression of the ARSI gene is mainly restricted to embryonic tissue and some cancer cell lines, 18 suggesting that ARSI is also not involved in the phenotype of the patients. In addition, no heterozygous variant predicting to lead to haploinsufficiency was observed in EVS for ARSI.
In conclusion, we describe for the first time, two patients with MFD and ID and for whom a deletion encompassing TCOF1 and CAMK2A has been identified. Based on the knowledge of the deleted genes in the two patients, we hypothesize that CAMK2A is in part responsible for ID and TCOF1 is responsible for the facial features. However, we cannot rule out a combinatorial effect with the other deleted genes. To our opinion, the genetic disorder observed in the two patients is to be considered as a contiguous gene deletion syndrome due to the combination of the effect of the loss of the TCOF1 gene and other genes such as CAMK2A. We suggest investigating for 5q32 deletion covering TCOF1 and CAMK2A if TCS is associated with ID without microcephaly, and to analyze EFTUD2 if TCS is associated with ID and microcephaly.
